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Background: We conducted this study is to investigate the correlation between stereopsis dysfunction and
color perception, as well as whether stereopsis impairment is associated with motor dysfunction in patients with
Parkinson’s disease (PD).
Method: Our present study included 45 PD patients and 50 non-PD control patients attending the Movement
Disorder Center at Xuanwu Hospital Capital Medical University in Beijing from July 2011 to November 2011.
Neurologic evaluations and visual function assessments were conducted, and the results between two groups
of patients were compared.
Results: We found that the total error scores (TESs) and partial error scores (PESs) for red, green, blue and purple
were all significantly higher in PD patients than in control patients. The limited grade on the FLY Stereo Acuity
Test with LEA Symbols was significantly lower in PD patients than in control patients (P = 0.0001), whereas the
percentage of abnormal stereopsis in PD patients was significantly higher than in control patients (42.2% vs. 12%;
P = 0.001). Multiple linear regression analysis showed that PD patients with higher Hoehn and Yahr Scale stage,
and those with decreased stereopsis had higher Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores
and worse motor function. Furthermore, our study demonstrates that the UPDRS motor scores and total average
number of the Purdue Pegboard Test scores of PD patients were significantly improved when they had taken
their medications, and the TESs and PESs for green were lower in when they were off their medications.
Conclusion: Our results provide more information on the underlying mechanisms of vision, motor and stereopsis
impairments in PD patients.
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Visual dysfunction is a common nonmotor symptom in
Parkinson’s disease (PD) that has several manifestations.
The impairment in color discrimination is one of the
most well-established visual deficits in PD patients [1-3].
It can be caused by peripheral retinal dopaminergic defi-
ciency [4-6] or by central visual impairments such as
orientation impairments [7,8], motion detection deficit
[9,10] and abnormal visual attention [11,12].* Correspondence: liangsun3@gmail.com; pbchan@hotmail.com
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unless otherwise stated.Recently, in a small study of PD patients, researchers
found stereopsis dysfunction to be related to visual cogni-
tive dysfunction [13]. Interestingly, to date, there has been
no simultaneous assessment of the potential influence of
peripheral abnormality on stereopsis impairment, which
could also be triggered once normal cortex is fed with
erroneous information from peripheral pathways such
as retinal ganglion cells.
In our present cross-sectional study, we first examined
the putative interdependence of color perception and
stereopsis abnormalities between PD patients and age-
matched control patients. We then analyzed the correla-
tions between visual deficits and patients’ demographic
features or motor dysfunction. Moreover, we compared. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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states to try to further clarify the correlation of stereopsis
function with color perception, visual function and motor
function in PD patients. Because color perception can be
improved with levodopa therapy, we tested whether this
treatment can also improve stereopsis dysfunction.
Methods
Patients
Between July 2011 and November 2011, 114 PD patients
were recruited at the Movement Disorder Center at
Xuanwu Hospital Capital Medical University in Beijing,
China, to participate in the study. All patients signed the
consent forms for participation. All experimental and
clinical procedures were reviewed and approved by the
Ethics Committee of Xuanwu Hospital, Capital Medical
University.
The diagnosis of movement disorders in PD patients
was made according to the UK Parkinson’s Disease Society
Brain Bank clinical diagnostic criteria [14]. Patients with
identified brain lesions or any other neurological disorders
were excluded. Patients’ spouses and relatives were screened
to participate in this study as age-matched controls.
All participants underwent tests for visual acuity and
strabismus. To eliminate the influence of ametropia,
corrective lenses were permitted during the stereopsis
and color perception tests. The exclusion criteria were
presence of strabismus, nystagmus, ocular motility dis-
turbance or poor visual acuity, even after correction in
either eye (<20/40 Snellen fraction). Furthermore, the
patients were asked about their history of eye diseases.
Those with a history of unoperated symptomatic cataracts,
untreated glaucoma, diabetic eye disease, congenital color
blindness or significant cognitive impairment were also
excluded from the study. After applying these criteria, 19
of the 114 patients were excluded from the study.
Neurologic evaluation
Standardized neurologic examinations and clinical assess-
ments were performed. All evaluations were carried out
in the morning, and patients were asked not to take
any antiparkinsonian medications for at least 12 hours
(18 hours for combined levodopa and carbidopa) to
ensure a practically defined off state [15]. The Hoehn
and Yahr (H&Y) stage and Unified Parkinson’s Disease
Rating Scale (UPDRS) scores were determined. The Purdue
Pegboard Test (PPT) was used to test hand dexterity and
motor speed. Briefly, this test requires the person to place
as many pins as possible in vertical columns of holes on a
board within 30 seconds. The pins were placed in the right,
left and both hands three times for each, and the average
number of the pins placed under the three conditions were
recorded. The total average number (TAN) of Purdue Peg-
board Test scores was used as the measurement method.Seven patients who had obvious “on and off” pheno-
menon were evaluated on the basis of two sets of UPDRS
score, H&Y stage and PPT scores: after they had taken
or not taken their usual antiparkinsonian medication. The
Mini Mental State Examination (MMSE) and Montreal
Cognitive Assessment (MoCA) were used to assess patients’
cognitive function.Visual function assessment
Patients were evaluated for visual function in the morning
in while not taking medication. All participants under-
went tests of visual acuity and strabismus. Their medical
histories of eye diseases were also recorded. Patients were
excluded from the study if they had strabismus, nystagmus,
ocular motility disturbance and/or poor visual acuity, even
after correction in either eye (<20/40 Snellen fraction). In
addition, patients with any of the following conditions were
excluded on the basis of a history of any of the following:
unoperated symptomatic cataracts, untreated glaucoma,
diabetic eye disease, congenital color blindness and/or
significant cognitive impairment. All visual function
tests were conducted in natural daylight while avoiding
direct sunlight. Stereopsis was assessed using the FLY
Stereo Acuity Test with LEA Symbols (P/N 1000; Vision
Assessment, Elk Grove Village, IL, USA). This test includes
10 grades, in descending order from 400 to 20 seconds
of arc. The limited grade (LG) of the FLY Stereo Acuity
Test with LEA Symbols was used as the index of partici-
pants’ stereopsis function. Normal stereopsis was defined
as LG ≥5 (arc ≥63 seconds). Color perception was tested
using Farnsworth-Munsell 100-Hue Test scores without
time limits. The total error scores (TESs) and partial error
scores (PESs) for red (caps 85 to 21), green (caps 22 to
42), blue (caps 43 to 63) and purple (caps 64 to 85)
were measured.Statistical analysis
Data were analyzed using SPSS version 11.5 software
(SPSS, Chicago, IL, USA). As age might influence visual
function [16], comparisons of visual function between
PD patients and controls were performed with one-way
analysis of variance, including age as a confounding co-
variate. To assess the characteristics of participants with
normal or abnormal stereopsis, a t-test was carried out.
The logistic regression model was used to determine the
independent risk factors for stereopsis impairment in PD
patients. The multiple linear regression model was used
to study the independent factors affecting color perception
and UPDRS part III score in PD patients. Visual and
motor functions in PD patients while taking or not taking
medication were assessed by performing a paired t-test.
Differences were considered to be significant if the P-value
was <0.05.
Table 1 Demographic features of the patientsa
Demographic features PD patients (n = 45) Controls (n = 50)
Age (yr) (means ± SD) 65.40 ± 9.37 65.48 ± 7.97
Sex (% male) 57.8 44.0
Body mass index (kg/m2) (means) 29.2 28.6
Marital status (ever-married) (n) 40 42
Duration of education (yr) (means) 8.7 7.9
Annual household income (Chinese yuan) (means) 64,320 62,325
H&Y stage (means ± SD) 2.22 ± 0.68 NA
UPDRS part III score (means ± SD) 25.18 ± 13.06 NA
UPDRS total score (means ± SD) 42.47 ± 19.71 NA
TAN (PPT scores) (means ± SD) 34.28 ± 10.12b 49.56 ± 6.50
MMSE score (means ± SD) 27.50 ± 3.09 28.36 ± 2.44
MoCA score (means ± SD) 23.95 ± 5.03 24.64 ± 4.37
Motor disease duration (yr) (means ± SD) 6.60 ± 4.52 NA
Hypertension (n) 8 10
Hyperthyroidism (n) 2 3
Diabetes (n) 9 8
aH&Y, Hoehn and Yahr; MMSE, Mini Mental State Examination; MoCA, Montreal Cognitive Assessment; NA, Not applicable; PD, Parkinson’s disease; PPT, Purdue
Pegboard Test; TAN, Total average number of Purdue Pegboard Test scores; UPDRS, Unified Parkinson’s Disease Rating Scale. bP = 0.0001.
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Patient characteristics
A total of 114 participants, comprising 53 PD patients
and 61 non-PD patients (controls), were included in this
study. From among these participants, 19 were excluded
because of concomitant brain lesions (n = 3), poor visual
acuity (n = 8), symptomatic cataracts (n = 6) or congeni-
tal color blindness (n = 2). As a result, 45 PD patients
(26 men and 19 women, mean age of 65.40 years, range
from 45 to 81 years) and 50 controls (22 men and 28
women, mean age of 65.48 years, range from 47 to
83 years) were enrolled into the study. The PD patients
had the following characteristics: mean H&Y stage 2.22 ±
0.68, mean UPDRS motor score 25.18 ± 13.06, mean
MMSE score 27.50 ± 3.09, mean MoCA score 23.95 ± 5.03Table 2 Pearson correlations between total average number
Data parameters PD patients (n = 45)
Correlation coefficient (t)
Age (yr) −0.127
Sex (% male) −0.196
H&Y stage −0.326
UPDRS part III score −0.620
UPDRS total score −0.579
MMSE score 0.100
MoCA score 0.237
Course of disease −0.229
aH&Y, Hoehn and Yahr stage; MMSE, Mini Mental State Examination; MoCA, Montre
Disease Rating Scale. bP < 0.05, cP < 0.01.and mean disease duration 6.60 ± 4.52 years. The mean
TAN (PPT scores) in PD patients was 34.28 ± 10.12, which
is significantly lower than the mean score of 49.56 ± 6.50
in controls (P = 0.0001). TAN (PPT scores) was correlated
with UPDRS total score, UPDRS motor score and H&Y
stage in PD patients (P = 0.0001, P = 0.0001 and P = 0.029,
respectively). However, they were not associated with
MMSE score, MoCA score or disease duration (P = 0.519,
P = 0.135 and P = 0.160, respectively). TAN (PPT scores)
was correlated with age in controls (P = 0.0001), as youn-
ger control participants had better values than elderly
ones. Overall, the demographic features of participants
and the clinical rating scales used to assess PD patients
are listed in Table 1. The TAN correlation factors are
shown in Table 2.of Purdue Pegboard Test scores and other factorsa
Controls (n = 50)









al Cognitive Assessment; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s
Table 3 Comparison of visual function in Parkinson’s disease patients and controls (adjusted for age)a
Visual function measurements PD patients (n = 45) Controls (n = 50) Adjusted P-value
Color perception (Farnsworth-Munsell 100-Hue Test score)
TES (mean ± SD) 135.82 ± 84.78 84.26 ± 41.73 0.0001b
PES (red) (mean ± SD) 33.18 ± 26.65 20.14 ± 14.40 0.001c
PES (green) (mean ± SD) 31.04 ± 17.66 19.90 ± 13.00 0.0001b
PES (blue) (mean ± SD) 45.33 ± 30.71 29.74 ± 14.35 0.001c
PES (purple) (mean ± SD) 26.22 ± 21.74 14.48 ± 10.35 0.0001b
Stereopsis
LG (mean ± SD) 5.16 ± 2.59 7.10 ± 1.89 0.0001b
Abnormal (%) 42.2% 12.0% 0.001c
aLG, Limited grade; PD, Parkinson’s disease; PES, Partial error score; TES, Total error score. bP < 0.001; cP < 0.05.
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patients and controls
We compared stereopsis and color perception between PD
patients and controls after matching for age between the
two groups. For color perception, the TES and PES for red,
green, blue and purple were all significantly higher in PD
patients than in controls (P = 0.0001, P = 0.001, P = 0.0001,
P = 0.001 and P = 0.0001, respectively). The LG values on
the FLY Stereo Acuity Test with LEA Symbols were signifi-
cantly lower in PD patients than in controls (P = 0.0001),
and the percentage of abnormal stereopsis in PD patients
(42.2%) was significantly higher than that in controlsTable 4 Comparison of Parkinson’s disease patients regarding
Data parameters PD patients (N = 45)
Normal stereopsis (n = 26) (mean ± SD) Abno
Age (yr) 64.58 ± 8.31 66.53
H&Y stage 2.04 ± 0.73 2.40 ±
UPDRS part III score 20.81 ± 7.48 31.16
UPDRS total score 37.15 ± 13.96 49.74
TAN (PPT scores) 37.41 ± 9.48 30.00
MMSE score 28.04 ± 1.74 26.78
MoCA score 24.96 ± 3.70 22.67
Line connection 0.66 ± 0.48 0.61 ±
Copy cube 0.76 ± 0.44 0.55 ±
Drawing clock 2.31 ± 0.97 2.06 ±
Disease duration (yr) 6.59 ± 5.34 6.61 ±
TES 110.85 ± 65.19 170.00
PES (red) 27.23 ± 23.31 41.32
PES (green) 23.96 ± 14.61 40.74
PES (blue) 39.04 ± 25.08 53.95
PES (purple) 20.54 ± 14.78 34.00
aH&Y, Hoehn and Yahr; MMSE, Mini Mental State Examination; MoCA, Montreal Cog
Pegboard Test; TAN, total average number; TES, Total error score; UPDRS, Unified Pa
logistic regression model was used with stereopsis (normal or abnormal) as the dep(12.0%) (P = 0.001). The comparisons of color perception
and stereopsis are presented in Table 3.Factors influencing color perception in Parkinson’s
disease patients
A multiple linear regression model was used to study
the factors influencing color perception in PD patients,
with TES used as the dependent variable. The probed
stereopsis factors included age, H&Y stage, UPDRS total
score, duration of disease, MMSE score, MoCA score,
TAN (PPT scores) and LG values. Our results show thatnormal vs abnormal stereopsisa
rmal stereopsis (n = 19) (mean ± SD) P-value Adjusted P-value
± 10.79 0.497
0.59 0.089
± 16.54 0.018b 0.112
± 24.14 0.033b









± 17.17 0.001c 0.027b
± 36.00 0.108
± 27.23 0.039b 0.409
nitive Assessment; PD, Parkinson’s disease; PES, Partial error score; PPT, Purdue
rkinson’s Disease Rating Scale. bP < 0.05; cP < 0.01. For the adjusted P-value, a
endent variable.
Table 5 Comparison of Unified Parkinson’s Disease Rating Scale motor scores between normal and abnormal stereopsis in
Parkinson’s disease patientsa
Patient characteristics PDNS (n = 26) (mean ± SD) PDAS (n = 19) (mean ± SD) P-value
Speech 0.42 ± 0.64 0.84 ± 1.02 0.097
Facial expression 1.04 ± 0.77 1.42 ± 0.61 0.081
Tremor at rest 2.15 ± 2.84 4.05 ± 3.81 0.063
Action or postural tremor of hands 0.85 ± 0.88 1.32 ± 1.25 0.146
Rigidity 4.88 ± 2.85 7.47 ± 3.50 0.009b
Finger taps 1.46 ± 1.07 2.79 ± 1.48 0.001b
Hand movements 1.73 ± 1.04 2.42 ± 1.07 0.036c
Rapid alternating movements 1.38 ± 1.06 2.47 ± 1.50 0.007b
Leg agility 1.12 ± 1.31 2.21 ± 1.27 0.007b
Arising from chair 0.69 ± 1.49 0.58 ± 1.07 0.779
Posture 1.08 ± 0.56 1.11 ± 0.57 0.868
Gait 1.08 ± 0.65 0.95 ± 0.62 0.468
Posture stability 1.04 ± 1.22 0.84 ± 0.60 0.521
Body bradykinesia and hypokinesia 1.35 ± 0.80 1.63 ± 0.83 0.250
aPDAS, Parkinson’s disease patients with abnormal stereopsis; PDNS, Parkinson’s disease patients with normal stereopsis. bP < 0.01; cP < 0.05.
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with TES in PD patients (t = 2.583, P = 0.015).
Factors associated with stereopsis function in Parkinson’s
disease patients
To study the factors associated with stereopsis function,
PD patients with normal stereopsis (PDNS) and PD pa-
tients with abnormal stereopsis (PDAS) were compared.
These data are shown in Table 4. We found no significant
differences with regard to age, H&Y stage, disease duration
or MMSE and MoCA scores between PDNS and PDAS.
However, in PDAS, UPDRS total scores and UPDRS motor
scores were higher (P = 0.033 and P = 0.018, respectively),
whereas TAN (PPT scores) was lower (P = 0.014). The
TES and the PES for green and purple were significantly
higher in PDAS than in PDNS (P = 0.019, P = 0.001 and
P = 0.039, respectively). To study the independent riskTable 6 Paired comparison of motor function and visual func
taking medicationsa
Data parameters Off medication (n = 8) (mean ± SD)
H&Y stage 2.11 ± 0.50
UPDRS part III score 27.37 ± 13.01
TAN (PPT scores) 35.74 ± 8.65
TES 89.24 ± 30.74
PES (red) 12.43 ± 6.53
PES (green) 23.14 ± 9.34
PES (blue) 35.49 ± 18.12
PES (purple) 12.45 ± 7.88
Stereopsis (LG) 6.33 ± 1.82
aH&Y, Hoehn and Yahr; LG, Limited grade; MMSE, Mini Mental State Examination; M
Pegboard Test; TAN, Total average number; TES, Total error score; UPDRS, Unified Pfactors for stereopsis impairment in PD patients, we used
a logistic regression model. The factors with significant
mean values in one-factor analysis were examined using
this model. The results show that only the PES for
green remained significant, as the adjusted P-value was
0.027 and the odds ratio (OR) of the PES for green was
1.093 (approximately 1.010 to 1.182). In addition, when
we compared normal and abnormal stereopsis in the
controls, we found no significant differences in TAN
(PPT scores), TES or PESs in FMT(Farnsworth-Munsell
100-Hue Test).
The influence of visual function on motor symptoms in
PD patients was analyzed using a multiple linear regression
model. The UPDRS motor score was considered the
dependent variable, and age, H&Y stage, course of disease,
MMSE and MoCA scores, TES and LG values on the FLY
Stereo Acuity Test with LEA Symbols were used astion in 16 Parkinson’s disease patients taking vs not
On medication (n = 9) (mean ± SD) t P-value
1.94 ± 0.52 1.902 0.110
10.24 ± 3.51 3.680 0.009b
44.33 ± 6.57 −3.78 0.007b
60.43 ± 30.55 2.764 0.025c
9.87 ± 7.95 1.114 0.376
12.56 ± 8.12 2.545 0.027c
29.01 ± 17.50 1.227 0.290
10.67 ± 8.54 0.711 0.574
6.64 ± 2.07 −1.023 0.377
oCA, Montreal Cognitive Assessment; PES, Partial error score; PPT, Purdue
arkinson’s Disease Rating Scale. bP < 0.05; cP < 0.01.
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on the FLY Stereo Acuity Test with LEA Symbols (P =
0.008) and H&Y stage (P = 0.018) were independently
associated with UPDRS motor scores. Our results also
show that PD patients with higher H&Y stages and de-
creased stereopsis had higher UPDRS motor scores and
worse motor function. PDAS had higher scores on the
UPDRS part III in rigidity, finger taps, hand move-
ments, rapid alternating movements and leg agility, than
those of PDNS (P = 0.009, P = 0.001, P = 0.036, P = 0.007
and P = 0.007, respectively) (Table 5).Comparison of visual function between medication on
and off states in Parkinson’s disease patients
The UPDRS motor scores and TAN (PPT scores) of the
16 PD patients were significantly improved while taking
medications (P < 0.05 and P < 0.05, respectively) (Table 6).
TES and PESs for green were lower while taking medica-
tions vs not (P < 0.05). We found no difference in stereopsis
between when the patients were or were not taking medica-
tion (P > 0.05).Discussion
The complex process of stereopsis is governed mainly by
the cerebral extrastriatal cortex [17,18]. Stereopsis impair-
ments have been reported in patients with supratentorial
lesions [19]. Little is known, however, about the under-
lying mechanisms of stereopsis dysfunction in Parkinson’s
disease, because not only central but also peripheral visual
pathways are involved.
In the present study, we show that PD patients made
more errors in color discrimination tests and had prom-
inent deficits on the green and purple axes. These results
are in line with those reported in previous studies show-
ing that blue cone deficiency is predominant in older PD
patients [20] and that nonmotor impairments, including
color discrimination deficits, are highly associated with
PD [2,4]. Interestingly, our study demonstrates that color
discrimination deficits were independent of the progres-
sion of PD, suggesting that the factor of age might be the
sole independent risk factor to consider in determining
the severity of retinal impairment in PD patients [16].
Our results also demonstrate that more PD patients
(19 (42.2%) of 45) than control patients (6 (12%) of 50)
had abnormal stereopsis. This result cannot be explained
as simply an age-related decrease in stereopsis, as shown
in previous studies [21,22], because PD patients and
controls were age-matched in our study. Furthermore,
we found that PDAS performed significantly worse in
motor function tests than PDNS and that abnormal
stereopsis was highly associated with decreased color
perception in PD patients. Taken together, these resultsstrongly suggest that stereopsis impairment might be
closely associated with the progression of PD.
Conclusions
Overall, the results of our study show that stereopsis
impairment is highly associated with color perception
and motor dysfunction in PD patients. Multiple factors,
in the central as well as peripheral visual pathways, may
work congruently in contributing to the pathology of ste-
reopsis. Also, stereopsis impairment severely aggravates
motor dysfunction in patients with PD. Thus, our results
provide further information on the underlying mechanisms
of stereopsis impairment, as well as their correlation with
the development of cognitive dysfunction in PD patients.
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